Search

Study Design: A retrospective study.Objective: The aim of this study was to detect risk factors for Adding-on after posterior correction surgery in patients with Lenke 1 or 2 AIS, and to explore whether Adding-on Index could be used to predict Adding-on effectively.Summary Of Background Data: Adding-on phenomenon is a common complication in Lenke 1 or 2 AIS patients after correction surgery. However, whether it can be predicted after surgery remains unknown.Methods: Lenke 1 or 2 AIS patients receiving correction surgery in our center from January 2009 to July 2013 were analyzed. Antero-posterior and lateral films were evaluated before surgery, at 2 weeks' and 2 years' follow-up. Patients were divided into 2 groups according to whether Adding-on occurred at the 2 years' follow-up. Risk factors of Adding-on were analyzed, and Adding-on Index was proposed and verified.Results: Sixteen patients (16.3%) suffered from distal Adding-on at 2-year follow-up. Several parameters were found to be significantly different between 2 groups, including Risser's sign, postoperative Cobb angle of main thoracic, postoperative Cobb angle of main thoracic curve at 2-year follow-up, preoperative and postoperative Cobb angle of lumbar curve, postoperative Cobb angle of lumbar curve at 2-year follow-up, LIV-EV, LIV-SV, LIV-CSVL, LAV-CSVL, LAV-LIV, DnfS, and postoperative TJK. No significant differences in SRS-22 scores were observed. Binary logistic regression analysis showed that DnfS and postoperative residual Cobb angle of lumbar curve were primary factors for occurrence of Adding-on. According to the regression equation, Adding-on Index was defined as 4 × DnfS-postoperative lumbar curves Cobb angle. On the basis of ROC curve, if Adding-on Index was more than 12, the occurrence rate of Adding-on was 88%. On the contrary, the rate of no Adding-on phenomenon was 80%.Conclusion: DnfS and posterior Cobb angle of lumbar curve were 2 important factors for Adding-on in Lenke 1, 2 AIS patients. Adding-on Index can be used to predict the occurrence of Adding-on effectively.Level Of Evidence: 4. [ABSTRACT FROM AUTHOR]

Objective: The objective of this study is to evaluate the clinical efficacy and toxicity of gefitinib single drug in treatment of advanced esophageal cancer.Materials and Methods: Forty-one case of advanced esophageal cancer were included from February 2012 to June 2016 in the Department of Oncology, Huaihe Hospital of Henan University. All of the included 41 cases were pathology or cytology confirmed of esophageal cancer with advanced stage with previously chemotherapy regimen of cisplatin or fluorouracil. The patients received gefitinib 250 mg/day orally until disease progression or development of unbearable drug-related toxicity. The objective response rate, overall survival, disease-free survival, and drug-related toxicity were recorded.Results: All of the 41 cases had evaluable lesions with complete response rate of 0.0% (0/41), partial response rate of 4.9% (2/41), stable disease rate of 34.1% (14/41), and progression disease rate of 61.0% (25/41). The objective response rate and disease control rate were 4.9% (2/41) and 39.0% (25/41), respectively. At the follow-up, end-point of October 2016, we observed 33 death of the included 41 patients with median disease progression time of 2.2 months and median survival time of 6.1 months; most of the drug-related toxicity was Grade 1-3 nonhematological toxicity with the incidence of Grade 1-2 rash of 51.2% (21/41), Grade 3-4 rash of 17.1% (7/41), Grade 1-2 diarrhea of 26.8% (11/41), Grade 3-4 diarrhea of 7.3% (3/41), Grade 1-2 nausea and vomiting of 14.6% (6/41).Conclusion: Gefitinib can improve the survival rate and quality of life in patients with advanced stage esophageal cancer who failed for first-line chemotherapy. [ABSTRACT FROM AUTHOR]